Pancrealipase Capsules 20,000 Units
Due to its enzymatic content, PANCREALIPASE is indicated in patients with digestive disorders associated with inadequate digestion of fats, carbohydrates, and proteins. Additionally, PANCREALIPASE is indicated in patients with exocrine pancreatic insufficiency and the symptoms associated with it, including: Acute pancreatitis, alcoholism, cystic fibrosis, chronic pancreatitis, post-pancreatectomy, gastrointestinal bypass surgery, and ductal obstruction caused by neoplasia. Common symptoms of pancreatic insufficiency include: Flatulence, diarrhea, feeling of fullness, abdominal distension, indigestion, excessive gas, and steatorrhea.
Pharmaceutical form
Capsule
Concentration
20,000 Units
Combination
N/A
Disclaimer: The content of this website is for pharmaceutical industry professionals interested in creating a strategic alliance with Wexford Laboratories. This page may contain information related to health, medical conditions, physical condition and its treatment. The information contained in this site is not to diagnose a health problem and is not a substitute for the advice provided by your doctor. Always consult a doctor when in doubt about a disease and its treatment. The products are subject to the applicable patent and registration laws of each country, and may not be allowed to be registered in some markets.
